CSI Con 2021 coverage: Role of GLP-1 receptor agonist in T2DM with Atherosclerotic Cardiovascular Disease

Published On 2021-12-03T11:06:56+05:30 | Updated On 3 Dec 2021 5:36 AM GMT

Overview

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are used to treat type 2 Diabetes Mellitus. GLP-1 RAs drugs are very effective in lowering blood sugar levels. These Drugs are also beneficial in improving heart health and kidney function.

In this Video, Dr. Prof. P.C. Manoria explains the Role of Glucagon-like peptide-1 receptor agonists in T2DM with Atherosclerotic Cardiovascular Disease. The leading cause of death in People with Type 2 Diabetes Mellitus (T2DM ) is CVD. T2DM doubles the risk of CVD compared with adults without T2DM.

Speakers

Dr P.C. Manoria

Dr. Prof. P.C. Manoria, MBBS, MD, DM, FICA (USA), FESC (Europe), FIAMS is a Director of Manoria Heart & Critical Care Hospital, Bhopal.Honorary Cardiologist, Earlier he was a Professor and Head Department of Cardiology, Gandhi Medical College, Bhopal. He was a Dean at the Indian College of Physicians, Indian College of Medical Ultrasound.